ANI Pharma Acquires Opana ER Rights for $8M

Ticker: ANIP · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1023024

Ani Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyAni Pharmaceuticals Inc (ANIP)
Form Type8-K
Filed DateJun 5, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: acquisition, drug-rights, financial-update

TL;DR

ANI Pharma buying Opana ER for $8M, deal closes Q3.

AI Summary

ANI Pharmaceuticals, Inc. announced on June 5, 2024, that it has entered into a definitive agreement to acquire the U.S. rights to the prescription drug Opana ER from Endo Pharmaceuticals Inc. for $8 million. This acquisition is expected to close in the third quarter of 2024.

Why It Matters

This acquisition expands ANI Pharmaceuticals' product portfolio with a prescription drug, potentially increasing revenue and market presence in the U.S.

Risk Assessment

Risk Level: medium — The acquisition involves integration risks and market performance uncertainties for the acquired drug.

Key Numbers

  • $8.0M — Acquisition Price (ANI Pharmaceuticals is paying $8 million for the U.S. rights to Opana ER.)

Key Players & Entities

  • ANI Pharmaceuticals, Inc. (company) — Acquiring company
  • Opana ER (drug) — Acquired product
  • Endo Pharmaceuticals Inc. (company) — Seller of rights
  • $8 million (dollar_amount) — Purchase price
  • June 5, 2024 (date) — Announcement date
  • third quarter of 2024 (date) — Expected closing period

FAQ

What specific U.S. rights is ANI Pharmaceuticals acquiring for Opana ER?

ANI Pharmaceuticals is acquiring the U.S. rights to the prescription drug Opana ER.

Who is the seller of the Opana ER rights?

The seller is Endo Pharmaceuticals Inc.

What is the total purchase price for the Opana ER rights?

The purchase price is $8 million.

When is the expected closing date for this acquisition?

The acquisition is expected to close in the third quarter of 2024.

What is the filing date of this 8-K report?

The filing date is June 5, 2024.

Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-05 07:59:24

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On June 5, 2024, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., will present at the 2024 Jefferies Global Healthcare Conference in New York City. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

01

Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated June 5 , 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 5, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.